Literature DB >> 17508983

Retrospective analysis of artemisinin pharmacokinetics: application of a semiphysiological autoinduction model.

Sara Asimus1, Toufigh Gordi.   

Abstract

AIMS: To describe the time-course of the autoinduction of artemisinin by applying a semi-physiological pharmacokinetic model.
METHODS: Plasma concentration-time data from six clinical studies involving oral administration of artemisinin to healthy subjects and malaria patients were included in the analysis. NONMEM was used to apply a semi-physiological model incorporating metabolizing enzymes and a pharmacokinetic model including a separate hepatic compartment.
RESULTS: The model described the data well. The hepatic extraction ratio increased from 0.74 at pre-induced conditions to 0.98 after autoinduction of metabolism.
CONCLUSIONS: Our model successfully described the time-course of autoinduction of metabolism of artemisinin in subjects receiving oral artemisinin.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17508983      PMCID: PMC2000583          DOI: 10.1111/j.1365-2125.2006.02844.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  10 in total

1.  Xpose--an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM.

Authors:  E N Jonsson; M O Karlsson
Journal:  Comput Methods Programs Biomed       Date:  1999-01       Impact factor: 5.428

2.  Artemisinin kinetics and dynamics during oral and rectal treatment of uncomplicated malaria.

Authors:  M Ashton; D S Nguyen; V H Nguyen; T Gordi; N H Trinh; X H Dinh; T N Nguyen; D C Le
Journal:  Clin Pharmacol Ther       Date:  1998-04       Impact factor: 6.875

3.  Semi-mechanistic pharmacokinetic/pharmacodynamic modelling of the antimalarial effect of artemisinin.

Authors:  Toufigh Gordi; Rujia Xie; William J Jusko
Journal:  Br J Clin Pharmacol       Date:  2005-12       Impact factor: 4.335

4.  Use of saliva and capillary blood samples as substitutes for venous blood sampling in pharmacokinetic investigations of artemisinin.

Authors:  T Gordi; T N Hai; N M Hoai; M Thyberg; M Ashton
Journal:  Eur J Clin Pharmacol       Date:  2000-11       Impact factor: 2.953

5.  Artemisinin pharmacokinetics in healthy adults after 250, 500 and 1000 mg single oral doses.

Authors:  M Ashton; T Gordi; N H Trinh; V H Nguyen; D S Nguyen; T N Nguyen; X H Dinh; M Johansson; D C Le
Journal:  Biopharm Drug Dispos       Date:  1998-05       Impact factor: 1.627

6.  Artemisinin pharmacokinetics is time-dependent during repeated oral administration in healthy male adults.

Authors:  M Ashton; T N Hai; N D Sy; D X Huong; N Van Huong; N T Niêu; L D Công
Journal:  Drug Metab Dispos       Date:  1998-01       Impact factor: 3.922

7.  A semiphysiological pharmacokinetic model for artemisinin in healthy subjects incorporating autoinduction of metabolism and saturable first-pass hepatic extraction.

Authors:  Toufigh Gordi; Rujia Xie; Nguyen V Huong; Dinh X Huong; Mats O Karlsson; Michael Ashton
Journal:  Br J Clin Pharmacol       Date:  2005-02       Impact factor: 4.335

8.  Artemisinin pharmacokinetics and efficacy in uncomplicated-malaria patients treated with two different dosage regimens.

Authors:  Toufigh Gordi; Dinh Xuan Huong; Trinh Ngoc Hai; Nguyen Thi Nieu; Michael Ashton
Journal:  Antimicrob Agents Chemother       Date:  2002-04       Impact factor: 5.191

9.  Artemisinin induces omeprazole metabolism in human beings.

Authors:  U S Svensson; M Ashton; N H Trinh; L Bertilsson; X H Dinh; V H Nguyen; T N Nguyen; D S Nguyen; J Lykkesfeldt; D C Le
Journal:  Clin Pharmacol Ther       Date:  1998-08       Impact factor: 6.875

10.  Artemisinin autoinduction is caused by involvement of cytochrome P450 2B6 but not 2C9.

Authors:  Ulrika S H Simonsson; Britt Jansson; Trinh Ngoc Hai; Dinh Xuan Huong; Gunnel Tybring; Michael Ashton
Journal:  Clin Pharmacol Ther       Date:  2003-07       Impact factor: 6.875

  10 in total
  5 in total

1.  Interaction between artemether-lumefantrine and nevirapine-based antiretroviral therapy in HIV-1-infected patients.

Authors:  T Kredo; K Mauff; J S Van der Walt; L Wiesner; G Maartens; K Cohen; P Smith; K I Barnes
Journal:  Antimicrob Agents Chemother       Date:  2011-09-26       Impact factor: 5.191

2.  A model based assessment of the CYP2B6 and CYP2C19 inductive properties by artemisinin antimalarials: implications for combination regimens.

Authors:  Doaa A Elsherbiny; Sara A Asimus; Mats O Karlsson; Michael Ashton; Ulrika S H Simonsson
Journal:  J Pharmacokinet Pharmacodyn       Date:  2008-03-19       Impact factor: 2.745

3.  Artemisinin and CYP2A6 activity in healthy subjects.

Authors:  Sara Asimus; Trinh Ngoc Hai; Nguyen Van Huong; Michael Ashton
Journal:  Eur J Clin Pharmacol       Date:  2007-12-07       Impact factor: 2.953

4.  A mechanism-based population pharmacokinetic model for characterizing time-dependent pharmacokinetics of midostaurin and its metabolites in human subjects.

Authors:  Ophelia Q P Yin; Yanfeng Wang; Horst Schran
Journal:  Clin Pharmacokinet       Date:  2008       Impact factor: 6.447

Review 5.  Pharmacological considerations in the design of anti-malarial drug combination therapies - is matching half-lives enough?

Authors:  Ian M Hastings; Eva Maria Hodel
Journal:  Malar J       Date:  2014-02-20       Impact factor: 2.979

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.